50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
CEO of biggest PE firm predicts “social unrest” (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
One Stock Doubles Your Money, During Crisis? (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
One Stock Doubles Your Money, During Crisis? (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
NASDAQ:RKDA

Arcadia Biosciences - RKDA Stock Forecast, Price & News

$0.56
-0.06 (-9.74%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.51
$0.62
50-Day Range
$0.56
$1.07
52-Week Range
$0.51
$2.66
Volume
247,845 shs
Average Volume
215,112 shs
Market Capitalization
$12.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Arcadia Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
484.3% Upside
$3.25 Price Target
Short Interest
Healthy
2.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$490 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.74) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Basic Materials Sector

104th out of 169 stocks

Agricultural Production - Crops Industry

5th out of 12 stocks

RKDA stock logo

About Arcadia Biosciences (NASDAQ:RKDA) Stock

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.

Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Stock News Headlines

Arcadia Biosciences Inc Stock Quote RKDA
Arcadia Biosciences Misses Q4 EPS by 12c
Arcadia Biosciences Q4 2021 Earnings Preview
Arcadia Biosciences: Buy, Sell, or Hold
Arcadia Biosciences appoints CEO
Arcadia Biosciences (RKDA) Names Stan Jacot as CEO
See More Headlines
Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Company Calendar

Last Earnings
8/11/2022
Today
9/24/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:RKDA
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$3.50
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+484.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,660,000.00
Net Margins
-169.65%
Pretax Margin
-178.91%

Debt

Sales & Book Value

Annual Sales
$6.78 million
Book Value
$1.41 per share

Miscellaneous

Free Float
21,860,000
Market Cap
$12.34 million
Optionable
Not Optionable
Beta
-0.07

Key Executives

  • Ms. Pamela Haley (Age 50)
    CFO & Corp. Sec.
    Comp: $250.08k
  • Ms. Laura Pitlik (Age 48)
    Chief Marketing Officer
    Comp: $160.78k
  • Mr. Stanley E. Jacot Jr. (Age 52)
    Pres, CEO & Director
  • Ms. Belinda Yao
    VP of Operations
  • Mr. Brian Schaffer
    Sr. VP of Sales
  • Dr. Zhongjin Lu Ph.D. (Age 56)
    Director of Product Devel.
  • Mr. Kevin Hodges
    VP of Commercial Operations













RKDA Stock - Frequently Asked Questions

Should I buy or sell Arcadia Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings
or view top-rated stocks.

What is Arcadia Biosciences' stock price forecast for 2022?

1 equities research analysts have issued twelve-month target prices for Arcadia Biosciences' shares. Their RKDA share price forecasts range from $3.00 to $3.50. On average, they expect the company's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 484.3% from the stock's current price.
View analysts price targets for RKDA
or view top-rated stocks among Wall Street analysts.

How have RKDA shares performed in 2022?

Arcadia Biosciences' stock was trading at $1.04 on January 1st, 2022. Since then, RKDA shares have decreased by 46.5% and is now trading at $0.5562.
View the best growth stocks for 2022 here
.

When is Arcadia Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our RKDA earnings forecast
.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its earnings results on Thursday, August, 11th. The basic materials company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.14. The basic materials company earned $3.86 million during the quarter, compared to analyst estimates of $2.28 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 80.56% and a negative net margin of 169.65%. During the same quarter in the previous year, the company earned ($0.26) earnings per share.

When did Arcadia Biosciences' stock split?

Arcadia Biosciences shares reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.58%), Millennium Management LLC (0.11%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Lilian Shackelford Murray, Matthew T Plavan, Pamela Haley and Sarah Reiter.
View institutional ownership trends
.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $0.56.

How much money does Arcadia Biosciences make?

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $12.34 million and generates $6.78 million in revenue each year. The basic materials company earns $-14,660,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.

This page (NASDAQ:RKDA) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.